183499-57-2

• 常用中文名：4-((5-((4-(3-氯苯基)-3-氧代哌嗪-1-基)甲基)-1H-咪唑-1-基)甲基)苯甲腈
• 常用英文名：L-778,123
• CAS号：183499-57-2
• 分子式：C₂₂H₂₀ClN₅O
• 分子量：405.88
• 相关类别： 信号通路 代谢酶/蛋白酶 法呢基转移酶
• 发布时间：2016-02-12 22:01:44
• 更新时间：2026-07-09 10:23:15
• L-778123是FPTase和GGPTase-I双重抑制剂, IC50值分别为2 nM 和 98 nM。

名称

• 中文名: 4-((5-((4-(3-氯苯基)-3-氧代哌嗪-1-基)甲基)-1H-咪唑-1-基)甲基)苯甲腈
• 英文名: 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolyl methyl]-2-piperazinone
• 英文别名: 4-((5-((4-(3-Chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)imidazolyl-methyl]-2-piperazinone; Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]; 4-[(5-{[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl}-1H-imidazol-1-yl)methyl]benzonitrile; 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone; L 778123 free base,L778123 free base; 4-[5-[4-(3-Chlorophenyl)-3-oxopiperazin-1-ylmethyl]imidazol-1-ylmethyl]benzonitrile; L-778; 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolyl-methyl]-2-piperazinone; L-778123 FREE BASE; L-778123; L 778123; L778123; L-778,123; L 778,123; L778,123; 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; L-778123; L-778123 free base; 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]Benzonitrile; 1-(3-Chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone

物化性质

• 分子式: C₂₂H₂₀ClN₅O
• 分子量: 405.88
• 精确质量: 405.13600
• PSA: 65.16000
• LogP: 3.30818
• 储存条件: 室温，干燥密封

生物活性

• 描述: L-778123是FPTase和GGPTase-I双重抑制剂, IC50值分别为2 nM 和 98 nM。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> 代谢酶/蛋白酶 >> 法呢基转移酶
• 参考文献:

  [1]. Lobell RB, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther. 2002 Jul;1(9):747-758.

  [2]. Ghasemi S, et al. Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines. Adv Pharm Bull. 2013;3(1):73-77.